These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9684921)

  • 1. Topoisomerase II and the response to antileukemic therapy.
    Kaufmann SH; Gore SD; Miller CB; Jones RJ; Zwelling LA; Schneider E; Burke PJ; Karp JE
    Leuk Lymphoma; 1998 Apr; 29(3-4):217-37. PubMed ID: 9684921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
    Nair JS; Kancherla R; Seiter K; Traganos F; Tse-Dinh YC
    Ann N Y Acad Sci; 2000; 922():326-9. PubMed ID: 11193914
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
    Malek SN; Gore SD
    Leuk Res; 2003 Jan; 27(1):1-3. PubMed ID: 12479845
    [No Abstract]   [Full Text] [Related]  

  • 4. Topoisomerases in human leukemia.
    Peereboom D; Charron M; Kaufmann SH
    Adv Pharmacol; 1994; 29B():33-50. PubMed ID: 8996600
    [No Abstract]   [Full Text] [Related]  

  • 5. Culprit and victim -- DNA topoisomerase II.
    Kellner U; Sehested M; Jensen PB; Gieseler F; Rudolph P
    Lancet Oncol; 2002 Apr; 3(4):235-43. PubMed ID: 12067686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of topoisomerase II-targeted antineoplastic drugs.
    Osheroff N; Corbett AH; Robinson MJ
    Adv Pharmacol; 1994; 29B():105-26. PubMed ID: 8996604
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
    Eder JP; Chan V; Wong J; Wong YW; Ara G; Northey D; Rizvi N; Teicher BA
    Cancer Chemother Pharmacol; 1998; 42(4):327-35. PubMed ID: 9744779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of action of antileukemic agents in leukemia chemotherapy].
    Nakamura T
    Rinsho Ketsueki; 1996 May; 37(5):380-91. PubMed ID: 8691581
    [No Abstract]   [Full Text] [Related]  

  • 9. Alchemix, p53 and topoisomerase.
    Grand RJ; Stewart GS
    Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618
    [No Abstract]   [Full Text] [Related]  

  • 10. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
    Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D
    N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
    Mainwaring MG; Rimsza LM; Chen SF; Gomez SP; Weeks FW; Reddy V; Lynch J; May WS; Kahn S; Moreb J; Leather H; Braylan R; Rowe TC; Fieniewicz KJ; Wingard JR
    Leuk Lymphoma; 2002 May; 43(5):989-99. PubMed ID: 12148910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.
    Beck WT; Danks MK; Wolverton JS; Chen M; Granzen B; Kim R; Suttle DP
    Adv Pharmacol; 1994; 29B():145-69. PubMed ID: 8996606
    [No Abstract]   [Full Text] [Related]  

  • 17. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.
    Solary E; Bertrand R; Pommier Y
    Leuk Lymphoma; 1994 Sep; 15(1-2):21-32. PubMed ID: 7858500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA topoisomerase II poisons and inhibitors.
    Capranico G; Giaccone G; D'Incalci M
    Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
    [No Abstract]   [Full Text] [Related]  

  • 19. DNA topoisomerase-trapping antitumour drugs.
    Capranico G; Zunino F
    Eur J Cancer; 1992; 28A(12):2055-60. PubMed ID: 1329885
    [No Abstract]   [Full Text] [Related]  

  • 20. Function of topoisomerase II and the consequences of inhibition.
    Davies SM
    Med Pediatr Oncol Suppl; 1996; 1():12-9. PubMed ID: 8643041
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.